216 related articles for article (PubMed ID: 16231719)
21. Factors influencing first remission and survival in 145 dogs with lymphoma: a retrospective study.
Baskin CR; Couto CG; Wittum TE
J Am Anim Hosp Assoc; 2000; 36(5):404-9. PubMed ID: 10997515
[TBL] [Abstract][Full Text] [Related]
22. Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.
Saba CF; Hafeman SD; Vail DM; Thamm DH
J Vet Intern Med; 2009; 23(5):1058-63. PubMed ID: 19678892
[TBL] [Abstract][Full Text] [Related]
23. A randomized controlled trial of the effect of prednisone omission from a multidrug chemotherapy protocol on treatment outcome in dogs with peripheral nodal lymphomas.
Childress MO; Ramos-Vara JA; Ruple A
J Am Vet Med Assoc; 2016 Nov; 249(9):1067-1078. PubMed ID: 27767437
[TBL] [Abstract][Full Text] [Related]
24. [A clinical observation of treatment of peripheral T-cell lymphoma with L-asparaginase-containing combination chemotherapy].
Yao G; Xie W; Zhou D; He D; He J; Shi J; Luo Y; Zheng W; Wei G; Lin M; Ye X; Cai Z; Huang H
Zhonghua Nei Ke Za Zhi; 2015 Feb; 54(2):111-7. PubMed ID: 25907840
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma.
Moore AS; Cotter SM; Rand WM; Wood CA; Williams LE; London CA; Frimberger AE; L'Heureux DA
J Vet Intern Med; 2001; 15(4):348-54. PubMed ID: 11467592
[TBL] [Abstract][Full Text] [Related]
26. Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?
Marconato L; Bonfanti U; Stefanello D; Lorenzo MR; Romanelli G; Comazzi S; Zini E
Vet Comp Oncol; 2008 Jun; 6(2):80-9. PubMed ID: 19178667
[TBL] [Abstract][Full Text] [Related]
27. Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma.
Lautscham EM; Kessler M; Ernst T; Willimzig L; Neiger R
Vet Rec; 2017 Mar; 180(12):303. PubMed ID: 28100766
[TBL] [Abstract][Full Text] [Related]
28. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
Wang SL; Lee JJ; Liao AT
Can Vet J; 2016 Mar; 57(3):271-6. PubMed ID: 26933263
[TBL] [Abstract][Full Text] [Related]
29. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Yong W; Zheng W; Zhu J; Zhang Y; Wei Y; Wang X; Lin N; Xie Y; Xu B; Li J
Hematol Oncol; 2006 Mar; 24(1):28-32. PubMed ID: 16323259
[TBL] [Abstract][Full Text] [Related]
30. Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs.
Rassnick KM; Bailey DB; Malone EK; Intile JL; Kiselow MA; Flory AB; Barlow LL; Balkman CE; Barnard SM; Waite AH
Vet Comp Oncol; 2010 Dec; 8(4):243-53. PubMed ID: 21062406
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.
Siedlecki CT; Kass PH; Jakubiak MJ; Dank G; Lyons J; Kent MS
Can Vet J; 2006 Jan; 47(1):52-9. PubMed ID: 16536229
[TBL] [Abstract][Full Text] [Related]
32. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
Flory AB; Rassnick KM; Al-Sarraf R; Bailey DB; Balkman CE; Kiselow MA; Autio K
J Vet Intern Med; 2008; 22(1):164-71. PubMed ID: 18289305
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
Chun R; Garrett LD; Vail DM
J Vet Intern Med; 2000; 14(2):120-4. PubMed ID: 10772481
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs.
Rassnick KM; Moore AS; Collister KE; Northrup NC; Kristal O; Chretin JD; Bailey DB
J Vet Intern Med; 2009; 23(2):317-22. PubMed ID: 19192147
[TBL] [Abstract][Full Text] [Related]
35. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma.
Hosoya K; Kisseberth WC; Lord LK; Alvarez FJ; Lara-Garcia A; Kosarek CE; London CA; Couto CG
J Vet Intern Med; 2007; 21(6):1355-63. PubMed ID: 18196747
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
Burton JH; Garrett-Mayer E; Thamm DH
Vet Comp Oncol; 2013 Dec; 11(4):306-15. PubMed ID: 22548975
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the Tolerability of Combination Chemotherapy with Mitoxantrone and Dacarbazine in Dogs with Lymphoma.
Intile JL; Rassnick KM; Al-Sarraf R; Chretin JD
J Am Anim Hosp Assoc; 2019; 55(2):101-109. PubMed ID: 30653362
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma.
Al-Nadaf S; Rebhun RB; Curran KM; Venable RO; Skorupski KA; Willcox JL; Burton JH
BMC Vet Res; 2018 Nov; 14(1):356. PubMed ID: 30458771
[TBL] [Abstract][Full Text] [Related]
39. Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014).
Lenz JA; Robat CS; Stein TJ
J Small Anim Pract; 2016 Aug; 57(8):429-34. PubMed ID: 27251593
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
